Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025European Journal of NeurologyOpen Access

Prescription of Monoclonal Antibodies Against Calcitonin Gene‐Related Peptide for the Prophylaxis of Migraine in Austria: A Retrospective, Longitudinal Analysis of Nationwide Insurance Data

View Full Paper
Ask AI
Bookmark
Share

Authors

KZKarin ZebenholzerAGAndreas GleissWGWalter Gall

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows effective treatment persistence with monoclonal antibodies in migraine patients, suggesting reduced triptan use.

Key Points

  • Persistence with monoclonal antibodies for migraine prophylaxis was excellent, highlighting treatment effectiveness.
  • Among 8934 patients, 42.9% maintained treatment with CGRP‐mAbs for at least 1 year, indicating strong adherence.
  • Dispensation of triptans significantly decreased during treatment with monoclonal antibodies, pointing to a shift in medication use.
  • Nationwide insurance data provide valuable insights into the treatment patterns and outcomes for migraine patients.

Cite This Study

Zebenholzer et al. (2025) studied this question.

synapsesocial.com/papers/693624ad4fa91c937236c58fhttps://doi.org/10.1111/ene.70440
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study2021 · 22 citations
  2. 2Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data2021 · 15 citations
  3. 3Health care resource utilization and direct costs incurred over 12 months by patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibodies: A US real-world study2025 · 1 citations
  4. 4Fremanezumab for the Preventive Treatment of Chronic Migraine2017 · 819 citations
  5. 5The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study2020 · 132 citations